Zynteglo halt re-ignites viral vector safety concerns; analystsBluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of Share XZynteglo halt re-ignites viral vector safety concerns; analystshttps://pharmaphorum.com/news/zynteglo-halt-re-ignites-viral-vector-safety-concerns-analysts/
bluebird bio ‘baffled’ after NICE rejects beta-thalassaemia gene therapyIt’s back to the drawing board for bluebird bio and its discussions with NICE, which has rejected its Share Xbluebird bio ‘baffled’ after NICE rejects beta-thalassaemia gene therapyhttps://pharmaphorum.com/news/bluebird-bio-baffled-after-nice-rejects/
bluebird offers instalment payments for Zynteglo gene therapybluebird bio is pricing its thalassaemia gene therapy Zynteglo at €1.57 million ($1.8 million) in Europe, but with Share Xbluebird offers instalment payments for Zynteglo gene therapyhttps://pharmaphorum.com/news/bluebird-offers-instalment-payments-for-zynteglo-gene-therapy/
bluebird claims first approval for gene therapy Zynteglo in EUbluebird bio has its first ever product approval, getting a green light from the EMA for Zynteglo, its Share Xbluebird claims first approval for gene therapy Zynteglo in EUhttps://pharmaphorum.com/news/bluebird-claims-first-approval-for-gene-therapy-zynteglo-in-eu/
bluebird bio gets CHMP nod for gene therapy ZyntegloA European Medicines Agency advisory panel has recommended a conditional approval for Zynteglo, bluebird bio’s lead gene therapy Share Xbluebird bio gets CHMP nod for gene therapy Zynteglohttps://pharmaphorum.com/news/bluebird-bio-gets-chmp-nod-for-gene-therapy-zynteglo/
